Form 4: Carlyle Group Sells Additional Shares of QuidelOrtho Corp (QDEL)

The Carlyle Group continues to reduce its stake in QuidelOrtho Corp through a series of sales executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• The Carlyle Group, a significant shareholder of QuidelOrtho Corp (QDEL), has reported the sale of shares of common stock.
• The sales occurred on July 16 and July 17, 2024.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on May 12, 2024.
• A total of 6,736 shares were sold on July 16 at a weighted average price of $31.7621, 25,995 shares at $32.309, 47,839 shares at $33.5203 and 14,291 shares at $34.13.
• On July 17, 2024, 65,670 shares were sold at a weighted average price of $34.7927 and 3,967 shares at $35.0343.
• Following these transactions, the Carlyle Investor beneficially owns 10,730,064 shares of QuidelOrtho Corp.
• The reporting entities include The Carlyle Group Inc. and several related entities, all of whom disclaim beneficial ownership of the securities except for the Carlyle Investor.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting share sales. It doesn't convey strong positive or negative sentiment, but continued selling pressure could be a slight negative.

Risks

• Continued sales by The Carlyle Group could exert downward pressure on QDEL's stock price.

Future Outlook

The Carlyle Group may continue to sell shares of QuidelOrtho Corp under the existing Rule 10b5-1 trading plan.

Industry Context

Share sales by major holders are common and can reflect portfolio adjustments or profit-taking strategies. The impact on QuidelOrtho's stock will depend on market perception and overall investor sentiment.

Stakeholder Impact

• Shareholders may experience short-term price fluctuations due to the share sales.
• The company's stock price could be affected by the continued selling pressure from a major shareholder.

Key Dates